United Therapeutics company profile
Company profile
United Therapeutics has 1,400 employees and is headquartered in Silver Spring, United States.
Based in Silver Spring, Maryland, United Therapeutics Corporation has existed since 1996 and develops and commercializes products for patients with chronic and life-threatening diseases. Its treatments for pulmonary arterial hypertension form the core of its range, including the inhaled Tyvaso DPI and Nebulized Tyvaso, the injectable Remodulin, the tablet Orenitram and the oral Adcirca. It also sells Unituxin, a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump, a pump and controller for Remodulin. Its pipeline spans idiopathic pulmonary fibrosis, organ xenotransplantation and regenerative medicine, developed in part through licensing and collaboration agreements with DEKA Research & Development Corp., MannKind Corporation and Arena Pharmaceuticals, Inc.
In the fiscal year ended December 2025, revenue rose 10.6% to 3.2 billion US dollars, and net profit reached 1.3 billion dollars. The United States generated 95.4% of revenue, while non-US markets accounted for 4.6%. The company employed 1,400 people.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Headquarters
- 1000 Spring Street, 20910, Silver Spring
- Employees
- 1,400
- Chief executive
- Martine Rothblatt
- Founded
- 1996
- Fiscal year
- January - December
- Listing
- UTHR · NASDAQ
- Currency
- USD
- ISIN
- US91307C1027
- Website
- unither.com
United Therapeutics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| United TherapeuticsUTHR | United States | $25.04B | 1,400 | 39.4% | 22.2 |
| ViatrisVTRS | United States | $23.58B | 30,000 | — | — |
| ZoetisZTS | United States | $33.92B | 14,500 | 37.9% | 14.1 |
| Neurocrine BiosciencesNBIX | United States | $16.73B | 2,500 | 26.6% | 24.5 |
| Teva Pharmaceutical IndustriesTEVA | United States | $49.67B | 31,173 | 19.8% | 99.0 |
| Hims & Hers HealthHIMS | United States | $4.13B | 2,442 | -6.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
